
Some additional thoughts and comments on Moderna, its coronavirus vaccine, the stock’s valuation and Monday night’s $1.3 billion stock sale:
Of course, Moderna raised money. It was only one week ago that I described Moderna’s $23 billion enterprise value as “astonishingly high” for a company with no approved products and no appreciable revenue. Monday, it was $29 billion, with the stock reaching another all-time high of $80 per share, or four times the price from the beginning of the year.
What is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Please get me off your mailing list. Thank you.